Citadel Advisors
EVFM

Citadel Advisors’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Citadel Advisors’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-79,208
Closed -$90K – 14304
2022
Q2 		$90K Buy
79,208
+66,008
+500% +$109K ﹤0.01% 11512
2022
Q1 		$67K Sell
13,200
-5,480
-29% -$34.5K ﹤0.01% 12610
2021
Q4 		$105K Sell
18,680
-7,033
-27% -$59.8K ﹤0.01% 12678
2021
Q3 		$285K Buy
25,713
+4,173
+19% +$52.4K ﹤0.01% 11153
2021
Q2 		$365K Buy
21,540
+14,680
+214% +$278K ﹤0.01% 10791
2021
Q1 		$180K Buy
6,860
+3,160
+85% +$144K ﹤0.01% 11832
2020
Q4 		$134K Buy
3,700
+920
+33% +$33.3K ﹤0.01% 10018
2020
Q3 		$98K Buy
2,780
+2,073
+293% +$90.1K ﹤0.01% 9285
2020
Q2 		$30K Buy
707
+40
+6% +$2.7K ﹤0.01% 9464
2020
Q1 		$53K Buy
+667
New +$53.4K ﹤0.01% 9008

Other funds holding EVFM

CS
Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
LTI
Laffer Tengler Investments Nashville, Tennessee $782M AUM 33.6% 1-Year Est. Return

Citadel Advisors's EVFM Position: Q3 2022 in Review

Citadel Advisors sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q3 2022, closing a stake of 210,122 shares — an estimated $238K sold.

Citadel Advisors first reported a position in EVFM in Q3 2016 and held it in 12 quarters. The position peaked at $238K in Q2 2022. 8 funds tracked by Wall St. Rank hold EVFM as of Q3 2022.

  • Citadel Advisors reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Citadel Advisors sold 210,122 Evofem Biosciences, Inc. Common Stock shares in Q3 2022, an estimated $238K.
  • Citadel Advisors first reported a position in Evofem Biosciences, Inc. Common Stock in Q3 2016 and held it in 12 quarters.
  • Citadel Advisors's Evofem Biosciences, Inc. Common Stock position peaked at $238K in Q2 2022.
  • 8 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q3 2022.

Based on Citadel Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.